Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic

Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date. The post Startup Treeline Bio Emerges From the Shadows With…

Read More

Listen: Why “TrumpRx” Might Not Save You Money

KFF Health News chief Washington correspondent Julie Rovner appeared Oct. 6 on the podcast “Today, Explained” to discuss TrumpRx, President Donald Trump’s proposal for a direct-to-consumer website aimed at lowering prescription drug costs. While few details were made public when the program was announced on Sept. 30, Rovner explains that consumers who are enrolled in…

Read More

Steps or Surgery: The Case for Wearables

Relentlessly, rates of chronic disease, depression, and medication use continue to rise — if there were ever a time to implement alternative preventive health tools in clinical practice, now is certainly it.  The post Steps or Surgery: The Case for Wearables appeared first on MedCity News.

Read More

Poll: While Most Adults Do Not Expect to Get a COVID-19 Shot This Fall, Those Who Want One Worry About Access and Insurance Coverage

As federal vaccine policy changes, most (59%) adults do not expect to get a COVID-19 vaccine this fall, while four in 10 (40%) say that they will “definitely” or “probably” get the shot, a new KFF Tracking Poll on Health Information and Trust finds. The groups most likely to say they will “probably” or “definitely”…More

Read More

Stick to the Science

By KIM BELLARD A year ago I wrote about disturbing news from the Pew Research Center that trust in science, and in scientists, had fallen since the pandemic. I am slightly relieved to report that a new follow-up study by Pew indicates that trust is up slightly – but still way below where they were…

Read More

Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals appeared first on MedCity…

Read More